ANI Pharmaceuticals, Inc.
ANIP
$82.11
-$0.56-0.68%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.57M | -10.21M | -21.05M | -18.52M | -7.09M |
| Total Depreciation and Amortization | 91.40M | 84.52M | 75.94M | 67.73M | 60.33M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.80M | 23.72M | 25.48M | 25.99M | 18.27M |
| Change in Net Operating Assets | 14.95M | 41.11M | 369.00K | -11.19M | 21.40M |
| Cash from Operations | 170.72M | 139.14M | 80.74M | 64.02M | 92.90M |
| Capital Expenditure | -14.99M | -13.69M | -14.13M | -16.24M | -16.12M |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 0.00 | 13.51M | 13.51M |
| Cash Acquisitions | -8.20M | -401.28M | -401.28M | -401.28M | -393.08M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -20.41M | -20.98M | -18.09M | -717.00K | -3.13M |
| Cash from Investing | -43.60M | -435.96M | -433.50M | -404.72M | -398.82M |
| Total Debt Issued | 0.00 | 641.25M | 641.25M | 641.25M | 641.25M |
| Total Debt Repaid | -6.25M | -298.59M | -297.31M | -296.03M | -296.63M |
| Issuance of Common Stock | 15.27M | 6.67M | 6.43M | 6.49M | 6.76M |
| Repurchase of Common Stock | -11.92M | -11.55M | -12.30M | -10.96M | -10.87M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.56M | -1.63M | -1.63M | -1.63M | -1.63M |
| Other Financing Activities | -5.75M | -61.68M | -61.68M | -74.18M | -80.95M |
| Cash from Financing | -10.22M | 274.47M | 274.77M | 264.95M | 257.93M |
| Foreign Exchange rate Adjustments | 725.00K | 74.00K | -767.00K | -470.00K | -75.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 117.63M | -22.28M | -78.76M | -76.23M | -48.06M |